1,721,599 research outputs found
THE EXPRESSION OF C-ERB-B2 IN HUMAN UROTHELIAL CARCINOMA
No full textObjectives To study the expression of c-erb-B2 in human urothelial cancer using an immunohistological (ABC) method. Material and Methods The staining characteristics of 86 tumors studied were analyzed with regards to grade, stage and outcome following treatment. Results Twenty-two, 9 and 20 tumors, respectively, were positive for c-erb-B2 out of 45, 15 and 26 G1, G2 and G3 tumors. Twenty-nine out of 55 pTa and pT1 tumors and 22 out of 31 muscle invasive tumors were positive for c-erb-B2. C-erb-B2 negative pTa and pT2 tumors were more commonly associated with no recurrence. Recurrences of higher grade and higher stage were more commonly associated with c-erb-B2 positive pTa and pT1 tumors. Conclusion Survival appeared to be more common in the c-erb-B2 negative muscle invasive tumors in comparison with the c-erb-B2 positive tumors.African Journal of Urology Vol. 7 No. 1 (Jan 2001): pp 13-1
C-erb B-2 amplification in cystic renal disease
No full textC-erb B-2 amplification in cystic renal disease. Gene amplification (overexpression) of c-erb B-2 was tested in a variety of cystic renal diseases, renal cell neoplasms (adenomas and carcinomas) and end stage kidneys without cysts C-erb B-2 encodes a receptor-like protein that shares homology with, but is distinct from the epidermal growth factor (EGF) receptor. A monoclonal antibody that immunoprecipitates a protein of approximately 185 kD from a lysate of NIH/3T3 cells transfected with the c-erb B-2 gene was utilized for testing. Simple renal cysts, cystic renal dysplasia, autosomal recessive polycystic kidney disease (ARPKD), and non-cystic, essentially normal kidneys failed to show c-erb B-2 overexpression. In contrast, autosomal-dominant polycystic kidney disease (ADPKD), acquired (dialysis-associated) cystic disease (ACD), non-cystic end stage kidneys and renal cell neoplasms revealed overexpression of c-erb B-2 with some frequency (40% or more of cases tested). Three cystic disorders revealing c-erb B-2 overexpression also showed platelet-derived growth factors (PDGFs) expression in similar locations (cyst lining and adjacent tubules). Other growth factors [insulin-like growth factor (IGF-I), fibroblast growth factor (FGF) and beta transforming growth factor (TGFβ)] were not noted to be overexpressed in either c-erb B-2 positive or negative cystic diseases C-erb B-2 may be a marker related to the proliferative/growth capabilities of selected cystic diseases, including potential for associated genesis of benign and malignant renal cell tumors
Prognostic Significance of CD44 and c-erb-B2 Protein Overexpression in Patients with Gastric Cancer
No full textBackground/Aims: The aim of the study is to evaluate the correlation between c-erb-B2 and CD44 overexpression and survival of patients with gastric cancer. Methodology: The paraffin blocks of 48 patients with gastric carcinoma were retrospectively analyzed. The pathological specimens were stained with CD44 and c-erb-B2 by immunohistochemical methods. Results: The positivity of c-erb-B2 was detected in 9 patients. In six of them, predominantly strong cytoplasmic staining was observed. The remaining three tumors were predominantly membranous stained. No correlation was found between the c-erb-B2 positivity and overall survival (OS). Seventeen specimens (35.4%) were CD44 positive, all localized in cell membrane. The median OS time of CD44 positive patients was worse than that of patients with CD44 negative (11 vs. 17 months, respectively). This difference was statistically significant (p=0.03). In 5 patients both CD44 and c-erb-B2 were detected as positive. However, there were 23 patients with both CD44 negative and c-erb-B2 negative. The median OS time for patients with both CD44 and cerb-B2 negative was better than those of patients with both CD44 and c-erb-B2 positive (37 vs. 11 months, respectively, p=0.03). The relationship between CD44 and c-erb-B2 positivities and clinicopathological factors (p>0.05). Conclusions: Our results showed that there was no correlation between c-erb-B2 positivity and OS, except for CD44. In addition, we found significant association of simultaneous positivities of c-erb-B2 and CD44 with OS of patients with gastric cancer. CD44 alone can be taken as a prognostic factor and also simultaneous overexpression of CD44 and c-erb-B2 may be used as a marker of poor prognosis
EXPRESSION OF C-ERB B-2 PROTEIN AND DNA-PLOIDY IN BREAST CARCINOGENESIS
No full textObjective.-to examine the c-erb B-2 expression and nuclear DNA content in samples of breast lesions to ascertain any relationship between c-erb B-2 expression and aneuploidy in the different types of proliferative breast lesions and in intraductal and invasive carcinomas.Design and Setting.-lmmunohistochemical analysis of c-erb B-2 expression and cytometric nuclear DNA assessment were performed in a series of 39 cases of intraductal hyperplasia without atypia, 7 cases of intraductal hyperplasia with atypia, 64 cases of intraductal carcinoma, and 85 cases of invasive breast carcinoma (30 of which had extensive intraductal component).Results.-Overexpression of c-erb B-2 was seen only in cases of carcinoma: 28 (43.7%) intraductal carcinomas and 15 (17.6%) invasive carcinomas. Aneuploidy was demonstrated in 3 (43.0%) cases of intraductal hyperplasia with atypia, in 54 (84.4%) cases of intraductal carcinoma, and in 63 (74.2%) cases of invasive carcinoma. All cases of intraductal hyperplasia without atypia were euploid and none expressed c-erb B-2. Among the carcinomas (intraductal and invasive) there was a strong relationship between aneuploidy and c-erb B-2 expression. In most instances, the intraductal and invasive components of the 30 invasive carcinomas with extensive intraductal component displayed similar DNA content and c-erb B-2 immunoreactivity; whenever there was a difference, the intraductal component tended to be aneuploid (five out of six cases) and c-erb B-2 positive (one case), in contrast to the respective invasive component.Conclusions.-The higher frequency of aneuploidy and c-erb B-2 expression in intraductal carcinomas in comparison with invasive carcinomas suggests there is not a linear relationship between DNA content abnormalities and neoplastic progression and that some invasive breast carcinomas evolve without an identifiable intraductal phase or are unrelated to disturbances at the c-erb B-2 locus
EXPRESSION OF C-ERB B-2 PROTEIN AND DNA-PLOIDY IN BREAST CARCINOGENESIS
No full textObjective.-to examine the c-erb B-2 expression and nuclear DNA content in samples of breast lesions to ascertain any relationship between c-erb B-2 expression and aneuploidy in the different types of proliferative breast lesions and in intraductal and invasive carcinomas.Design and Setting.-lmmunohistochemical analysis of c-erb B-2 expression and cytometric nuclear DNA assessment were performed in a series of 39 cases of intraductal hyperplasia without atypia, 7 cases of intraductal hyperplasia with atypia, 64 cases of intraductal carcinoma, and 85 cases of invasive breast carcinoma (30 of which had extensive intraductal component).Results.-Overexpression of c-erb B-2 was seen only in cases of carcinoma: 28 (43.7%) intraductal carcinomas and 15 (17.6%) invasive carcinomas. Aneuploidy was demonstrated in 3 (43.0%) cases of intraductal hyperplasia with atypia, in 54 (84.4%) cases of intraductal carcinoma, and in 63 (74.2%) cases of invasive carcinoma. All cases of intraductal hyperplasia without atypia were euploid and none expressed c-erb B-2. Among the carcinomas (intraductal and invasive) there was a strong relationship between aneuploidy and c-erb B-2 expression. In most instances, the intraductal and invasive components of the 30 invasive carcinomas with extensive intraductal component displayed similar DNA content and c-erb B-2 immunoreactivity; whenever there was a difference, the intraductal component tended to be aneuploid (five out of six cases) and c-erb B-2 positive (one case), in contrast to the respective invasive component.Conclusions.-The higher frequency of aneuploidy and c-erb B-2 expression in intraductal carcinomas in comparison with invasive carcinomas suggests there is not a linear relationship between DNA content abnormalities and neoplastic progression and that some invasive breast carcinomas evolve without an identifiable intraductal phase or are unrelated to disturbances at the c-erb B-2 locus
F22 C-ERB-B2: a new prognostic factor in NSCLC? Preliminary report of our experience
No full textStage of desease is a main prognostic factor (PF) for resected NSCLC (Mountain
1986). However the variety of clinical behaviour and the contradictory results of
adjuvant treatment let oncologists suppose other PF to be investigated Since 1st
january 1998 until 31st dicember 1998, 33 sequential patients (pts) with stage I
NSCLC were operated by General Surgery Department of University in San
Giuseppe General Hospital in Milan. Since the patients were all stage I no adjuvant
treatment was provided. 19 pts were operated with lobectomy (L) and 14 wedge
resection (WR). The patients follow-up lasts from 1998 until 31 december 2001. All
operated tumors were analized for c-erb-B2 expression (IHC determinated) quantified
in 0 , 1+, 2+ ,3+. At the time being 7 pts operated with L and 4 with WR are
death. 12 L and 10 WR are alive.
Results: in death patiens (11 pts): 7 pt (63.6%) with 0 or 1 + c-erb-B2 expression and
4 pts (34.4%) with 2+ or 3+ c-erb-B2 expression; in live pts without relapse disease
(17 pts): 15 pts (88%) with 0 or 1+ c-erb-B2 expression and 2 pts (12% ) with 2+
or 3+ c-erb-B2 expression; in live pts with relapse disease (5 pts): 5 pts (100%)
with 0 or 1+ c-erb-B2 expression; in all live pts (22 pts): 20 pts (91%) with 0 or 1+
c-erb-B2 expression and 2 pts (9%) with 2+ or 3+ expression.
c-erb-B2(0-1+) c-erb-B2level(2-3+)
death patients 7 (63.6%) 4 (34.4%)
live patients (no relapse) 15 (88%) 2 (12%)
live patients (with relapse) 5 (100%) 0
live patients (no relapse + relapse) 20 (91%) 2 (9%)
The percentage of death pts to 2+ or 3+ c-erb-B2 expression is 3 times superior to
the percentage of live pts (no relapse) to 2+ or 3+ c-erb-B2 expression, this
difference with at 4 times if compare death pts to all live pts (Cox test p= 0.002).
The expression of c-erb-B2 seems in this preliminary report to be an indipendent
prognostic factor in stage I radically operated NSCLC. Our study in still ongoing.
F23 A NEW SCHEDULING OF DAY 1 AND 8 EVERY THREE WEEK
EXPRESSION OF C-ERB B-2 PROTEIN AND DNA-PLOIDY IN BREAST CARCINOGENESIS
No full textObjective.-to examine the c-erb B-2 expression and nuclear DNA content in samples of breast lesions to ascertain any relationship between c-erb B-2 expression and aneuploidy in the different types of proliferative breast lesions and in intraductal and invasive carcinomas.Design and Setting.-lmmunohistochemical analysis of c-erb B-2 expression and cytometric nuclear DNA assessment were performed in a series of 39 cases of intraductal hyperplasia without atypia, 7 cases of intraductal hyperplasia with atypia, 64 cases of intraductal carcinoma, and 85 cases of invasive breast carcinoma (30 of which had extensive intraductal component).Results.-Overexpression of c-erb B-2 was seen only in cases of carcinoma: 28 (43.7%) intraductal carcinomas and 15 (17.6%) invasive carcinomas. Aneuploidy was demonstrated in 3 (43.0%) cases of intraductal hyperplasia with atypia, in 54 (84.4%) cases of intraductal carcinoma, and in 63 (74.2%) cases of invasive carcinoma. All cases of intraductal hyperplasia without atypia were euploid and none expressed c-erb B-2. Among the carcinomas (intraductal and invasive) there was a strong relationship between aneuploidy and c-erb B-2 expression. In most instances, the intraductal and invasive components of the 30 invasive carcinomas with extensive intraductal component displayed similar DNA content and c-erb B-2 immunoreactivity; whenever there was a difference, the intraductal component tended to be aneuploid (five out of six cases) and c-erb B-2 positive (one case), in contrast to the respective invasive component.Conclusions.-The higher frequency of aneuploidy and c-erb B-2 expression in intraductal carcinomas in comparison with invasive carcinomas suggests there is not a linear relationship between DNA content abnormalities and neoplastic progression and that some invasive breast carcinomas evolve without an identifiable intraductal phase or are unrelated to disturbances at the c-erb B-2 locus.UNIV ESTADUAL PAULISTA, SCH MED, DEPT PATHOL, P-4100 SAO PAULO, BRAZILUNIV PORTO, INST PATOL & IMMUNOL MOLEC, MOLEC PATHOL UNIT, OPORTO, PORTUGALINST CANC RES, DEPT PATHOL, COIMBRA, PORTUGALUNIV ESTADUAL PAULISTA, SCH MED, DEPT PATHOL, P-4100 SAO PAULO, BRAZI
Prognosis value of p53, C-erB-2 and Ki67 proteins in ovarian carcinoma
No full textThe prognosis in ovarian carcinoma remains poor. We need to identify patients who are less likely to respond to treatment. In order to evaluate the prognostic value of C-erb-B2, p53 and Ki 67 expression and correlate these markers with classic prognostic factors, we studied paraffin-embedded tumor tissue from 81 patients with epithelial ovarian cancer and made a quantitative evaluation of C-erb-B2, p53 and Ki 67 expression by immunohistochemistry. The results were: age 5.4 +/- 15(22-88); 66% with normal physical activity; 48.2% with residual disease < 2 cm; initial stage--42% and advanced stage--58%. Age, performance status, residual disease and stage were correlated with 2 and 5 years survival. Positive immunostaining: p53--87%, C-erb B-2--51% and Ki67--100%. P53 and C-erb B-2 were associated with residual disease and stage; patients with no C-erbB-2 staining had a significantly better survival. A direct and significant correlation was found between p53 and Ki67 and between C-erb B-2 and p53. We conclude that these markers have a high expression in ovarian carcinoma and p53 and C-er B-2 correlate with stage and residual disease. Although C-erb B-2 was associated with better survival, it was not found to be an independent prognostic factor
Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas Expressão de p53, Ki-67 e c-erb B2 em adenomas hipofisários secretores de prolactina e/ou hormônio de crescimento
No full textThe subcellular events implicated on the formation and behavior of pituitary adenomas are not fully understood. In this study we investigated the presence of p53, Ki-67 and c-erb B2 in 38 pituitary adenomas with immunohistochemical positivity for GH and prolactin (n=26; 68.4%), for prolactin (n=9; 23.7%) and for GH (n=3. 7.8%). The analyses revealed the following results: 24 (63.2%) tumors expressed variable positivity for c-erb B2, 11 (28.9%) expressed p53 positivity and 11 (28.9%) tumors were variably positive for Ki-67. Our results demonstrated a high percentage of GH/prolactin-, prolactin- and GH-secreting tumors with immunohistochemical positivity for c-erb B2. Once this membrane receptor is related to growth factors EGF and TGFalpha and both have a definite effect on tumor growth, our data suggest a possible role for c-erb B2 on the evolution of these tumors.Os eventos subcelulares implicados na formação e comportamento dos adenomas hipofisários não são completamente compreendidos. Neste estudo nós investigamos a presença de p53, Ki-67 e c-erb B2 em 38 adenomas hipofisários com positividade imuno-histoquímica para GH e prolactina (n=26, 68,4%), para prolactina (n=9, 23,7%) e para GH (n=3, 7,8%). A análise revelou os seguintes resultados: 24 tumores (63,2%) expressaram positividade variável para c-erb B2, 11 (28,9%) expressaram positividade para p53 e 11 tumores (28,9%) foram variavelmente positivos para Ki-67. Nossos resultados demonstraram elevada percentagem de tumores secretores de GH/prolactina, prolactina e GH com positividade imuno-histoquímica para c-erb B2. Desde que este receptor de membrana está relacionado aos fatores de crescimento EGF e TGFalfa e ambos têm efeito definido no crescimento tumoral, nossos dados sugerem possível função para o c-erb B2 na evolução destes tumores
C-ERB B2 EXPRESSION IN COLORECTAL CARCINOMA; ITS RELATIONSHIP WITH TUMOR GRADE AND OTHER PROGNOSTIC FACTORS
No full textObjective: The multidisciplinary management of colorectal carcinoma (CRC) is based on tumor stage, grade, and presence of vascular invasion. In this approach, information derived from the molecular characteristics of the tumor may be missed. There is a need to determine new prognostic parameters.Human epidermal growth factor 2 (c-erb B2) protein overexpression is implicated in the development of various tumor types, while the data on CRC is ambiguous. This study aimed at determining the frequency of c-erb B2 overexpression in CRC, checking it against prognostic parameters, as it has a special role in breast and gastric cancers.Material and Methods: A total of 71 colectomy specimens diagnosed as CRC at the Mustafa Kemal University Medical Faculty, Department of Pathology between January 2007, and December 2012, were included in this study. The c-erb B2 overexpression of tumor cells was detected by using immunohistochemistry (IHC).Results: Among the 71 CRC cases, 34 (47.9%) of them were c-erb B2 score 0, 22 (31%) of them were score 1, 10 (14.1%) of them were score 2, 5 (7%) of them were score 3.Conclusion: The overexpression of c-erb B2 protein was detected in 21.1% of CRC cases whereas no significant relationship with prognostic parameters was determine
- …
